Oracle
ORCL
Microsoft
MSFT
D.R. Horton
DHI
Lennar Corp
LEN
Amazon
AMZN
US Stock MarketDetailed Quotes
ALKS Alkermes
- 30.210
- +0.110+0.37%
Close Jan 22 16:00 ET
- 30.170
- -0.040-0.13%
Post 16:42 ET
4.89BMarket Cap15.26P/E (TTM)
30.390High29.925Low1.12MVolume29.930Open30.100Pre Close33.80MTurnover0.73%Turnover Ratio14.39P/E (Static)161.80MShares32.88052wk High3.78P/B4.64BFloat Cap22.90052wk Low--Dividend TTM153.46MShs Float98.500Historical High--Div YieldTTM1.55%Amplitude3.550Historical Low30.202Avg Price1Lot Size
About Alkermes Company
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Company Profile
SymbolALKS
Company NameAlkermes
Listing DateSep 19, 2011
Issue Price10.00
Founded2011
CEOMr. Richard F. Pops
MarketNASDAQ
Employees2100
Fiscal Year Ends12-31
AddressConnaught House,1 Burlington Road
CityDublin
ProvinceDublin
CountryIreland
Zip Code4
Phone353-1-772-8000
Websitehttp://www.alkermes.com
Company Executives
- Name
- Position
- Salary
- Richard F. Pops
- Chairman of the Board and Chief Executive Officer
- 9.44M
- Christian Todd Nichols
- Senior Vice President and Chief Commercial Officer
- --
- Blair C. Jackson
- Interim Chief Financial Officer; Executive Vice President and Chief Operating Officer of the Company and Alkermes, Inc.
- 4.56M
- Dr. Craig C. Hopkinson, M.D.
- Executive Vice President, Research and Development and Chief Medical Officer
- 4.73M
- Iain M. Brown
- Senior Vice President, Chief Financial Officer and Principal Accounting Officer
- 3.21M
- David Joseph Gaffin
- Executive Vice President, Chief Legal Officer, Secretary and Chief Compliance Officer
- 4.14M
- Samuel J. Parisi
- Interim Principal Accounting Officer; Vice President, Finance of Alkermes, Inc.
- --
- Shane M. Cooke
- Chairman of the Board; Alkermes Pharma Ireland Limited
- 449.04K
- David A. Daglio, Jr
- Independent Director
- 474.04K
- Dr. Nancy L. Snyderman, F.A.C.S.,M.D.
- Independent Director
- 482.04K
- Nancy S. Lurker
- Independent Director
- --
- Frank Anders Wilson
- Lead Independent Director
- 486.65K
- Dr. Christopher I. Wright, M.D.,PhD
- Independent Director
- 463.12K
- Emily Peterson Alva
- Independent Director
- 469.04K
- Brian P. Mckeon
- Independent Director
- 482.04K
- Dr. Richard B. Gaynor, M.D.
- Independent Director
- 464.69K
- Dr. Cato T. Laurencin,M.D.,PhD
- Independent Director
- 459.04K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.